Celcuity Inc. (CELC)

NASDAQ: CELC · IEX Real-Time Price · USD
15.99
-0.52 (-3.15%)
May 22, 2024, 4:00 PM EDT - Market closed
-3.15%
Market Cap 499.37M
Revenue (ttm) n/a
Net Income (ttm) -73.45M
Shares Out 31.23M
EPS (ttm) -2.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 74,854
Open 16.44
Previous Close 16.51
Day's Range 15.94 - 16.61
52-Week Range 8.39 - 22.19
Beta 0.87
Analysts Strong Buy
Price Target 29.50 (+84.49%)
Earnings Date May 15, 2024

About CELC

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 20, 2017
Employees 55
Stock Exchange NASDAQ
Ticker Symbol CELC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for CELC stock is "Strong Buy." The 12-month stock price forecast is $29.5, which is an increase of 84.49% from the latest price.

Price Target
$29.5
(84.49% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update

MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial re...

7 days ago - GlobeNewsWire

Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call

MINNEAPOLIS, May 08, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will...

14 days ago - GlobeNewsWire

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian...

6 weeks ago - GlobeNewsWire

Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

MINNEAPOLIS, March 27, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial ...

2 months ago - GlobeNewsWire

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call

MINNEAPOLIS, March 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it wi...

2 months ago - GlobeNewsWire

Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024

MINNEAPOLIS, March 06, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its partic...

2 months ago - GlobeNewsWire

Celcuity to Participate in Cowen's 44th Annual Health Care Conference

MINNEAPOLIS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its partici...

3 months ago - GlobeNewsWire

Celcuity Appoints Eldon Mayer as Chief Commercial Officer

MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appoint...

3 months ago - GlobeNewsWire

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium

MINNEAPOLIS, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today presented data from p...

6 months ago - GlobeNewsWire

Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium

MINNEAPOLIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abs...

6 months ago - GlobeNewsWire

Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference

MINNEAPOLIS, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its partici...

6 months ago - GlobeNewsWire

Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

MINNEAPOLIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today reported financial re...

6 months ago - GlobeNewsWire

Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call

MINNEAPOLIS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it wil...

7 months ago - GlobeNewsWire

Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences

MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian ...

7 months ago - GlobeNewsWire

Celcuity Inc. Announces $50 Million Private Placement

MINNEAPOLIS, MN / ACCESSWIRE / October 18, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, announced today that it h...

7 months ago - Accesswire

Celcuity to Host Virtual Science Day for Investors

MINNEAPOLIS, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it wi...

9 months ago - GlobeNewsWire

Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial

MINNEAPOLIS, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it has...

9 months ago - GlobeNewsWire

Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer

- Received FDA clearance of IND for gedatolisib in combination with darolutamide - Virtual Science Day to be held on September 21, 2023 from 10:00 a.m. – 12:00 p.m.

9 months ago - GlobeNewsWire

Celcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

MINNEAPOLIS, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today reported financial re...

10 months ago - GlobeNewsWire

Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call

MINNEAPOLIS, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it w...

10 months ago - GlobeNewsWire

Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023

MINNEAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that Bria...

10 months ago - GlobeNewsWire

Celcuity Set to Join Russell 2000 and 3000 Indexes

MINNEAPOLIS, MN / ACCESSWIRE / June 20, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, is set to join the Russell...

1 year ago - Accesswire

Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences

MINNEAPOLIS, MN / ACCESSWIRE / May 24, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that Brian ...

1 year ago - Accesswire

Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates

Presented updated results for treatment-naïve patients from Phase 1b study of gedatolisib at the ESMO Breast Cancer Annual Congress - median progression free survival (PFS) was 48.6 months Presented n...

1 year ago - Accesswire

Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress

Median progression free survival (PFS) was 48.6 months in treatment-naïve patients with HR+/HER2- advanced breast cancer who were treated with gedatolisib in combination with palbociclib and letrozole...

1 year ago - Accesswire